Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 1,157 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total transaction of $62,801.96. Following the completion of the transaction, the insider directly owned 18,971 shares of the company’s stock, valued at $1,029,745.88. The trade was a 5.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, September 4th, Jonathan Zalevsky sold 1,721 shares of Nektar Therapeutics stock. The stock was sold at an average price of $33.52, for a total transaction of $57,687.92.
• On Tuesday, September 2nd, Jonathan Zalevsky sold 485 shares of Nektar Therapeutics stock. The shares were sold at an average price of $30.10, for a total value of $14,598.50.

Nektar Therapeutics Trading Up 2.9%

NASDAQ NKTR opened at $60.35 on Wednesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -6.86 and a beta of 1.19. The stock has a 50-day moving average of $58.30 and a 200 day moving average of $34.92. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $66.92.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($2.85) by $1.00. The company had revenue of $11.79 million for the quarter, compared to analyst estimates of $10.20 million. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%. Equities analysts predict that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NKTR has been the subject of a number of research analyst reports. B. Riley upped their price objective on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Jefferies Financial Group reiterated a “buy” rating and issued a $121.00 price objective on shares of Nektar Therapeutics in a report on Monday. Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research note on Wednesday, November 19th. Finally, BTIG Research reiterated a “buy” rating and set a $100.00 price target on shares of Nektar Therapeutics in a research report on Friday, September 19th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.20.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Cerity Partners LLC acquired a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $52,000. CWM LLC increased its holdings in shares of Nektar Therapeutics by 4,544.5% in the first quarter. CWM LLC now owns 105,524 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 103,252 shares during the last quarter. Mackenzie Financial Corp lifted its position in Nektar Therapeutics by 253.1% during the first quarter. Mackenzie Financial Corp now owns 1,658,745 shares of the biopharmaceutical company’s stock worth $1,128,000 after buying an additional 1,188,976 shares in the last quarter. Deuterium Capital Management LLC acquired a new position in Nektar Therapeutics during the first quarter worth $381,000. Finally, US Bancorp DE grew its holdings in Nektar Therapeutics by 257.8% in the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 36,085 shares in the last quarter. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.